#CheckpointTherapeutics - Twitter Hashtag

over 1 year ago

🚨 CEO of Checkpoint Therapeutics sells $60,963 in stock! 💼 What does this move mean for the company's future? Find out more on my blog! 📈 #CheckpointTherapeutics #StockMarket #CEO #Investing #BusinessNews #Finance #StockAnalysis

0

2

0

41

Investment Guru India @InvGurInd

over 1 year ago

Sun Pharma rises on plans to acquire Checkpoint Therapeutics https://t.co/R52F9TcILs #StockMarket #PharmaSector @SunPharma_Live #CheckpointTherapeutics #Investmentguruindia

InvGurInd's tweet photo. Sun Pharma rises on plans to acquire Checkpoint Therapeutics

https://t.co/R52F9TcILs

#StockMarket #PharmaSector @SunPharma_Live #CheckpointTherapeutics #Investmentguruindia https://t.co/kOMMV8jdln

0

53

EquityBulls.com

@equitybulls

over 1 year ago

Sun Pharma to acquire Checkpoint Therapeutics @SunPharma_Live #SunPharmaceuticalIndustries #Acquisition #CheckpointTherapeutics #CKPT https://t.co/kTuLI7W1gk

0

3

0

367

Hottest Stocks Now @HottestStockNow

almost 2 years ago

Checkpoint Therapeutics: FDA OKs UNLOXCYT (cosibelimab-ipdl) to treat adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation $CKPT, #CheckpointTherapeutics https://t.co/wjPWrQmOQv

0

2

0

433

gilberto lopes

@GlopesMd

over 4 years ago

#FastFollower drugs have the potential to reduce costs and improve access to newer therapies in cancer. We need to come up with a better path to bring them to market. Competition is key! @ASCO @FDAOncology @EQRxInc #Checkpointtherapeutics @Coherus_Bio @ATOM_Coalition @uicc

Charu Aggarwal, MD, MPH, FASCO

@CharuAggarwalMD

over 4 years ago

Thrilled to see "Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?" in print. We discuss implications for clinical trial design, and cost, and access - with the brilliant @oncology_bg out in @JCO_ASCM #LCSM https://t.co/TAEClcTx2E

CharuAggarwalMD's tweet photo. Thrilled to see "Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?" in print. We discuss implications for clinical trial design, and cost, and access - with the brilliant @oncology_bg out in @JCO_ASCM #LCSM
https://t.co/TAEClcTx2E https://t.co/ogrJynaQds

9

83

28

11

0

3

16

7

1

0

Tickeron

@Tickeron

about 5 years ago

$CKPT soared +69.58% and reached a 3-month high. #CheckpointTherapeutics #stockmarket #stock Expect an Uptrend reversal. View odds: https://t.co/Lv1wLwcufW

0

2

0

Tickeron

@Tickeron

about 5 years ago

$CKPT enters bullish trend #CheckpointTherapeutics #stockmarket #stock https://t.co/QIe7eekkKh

0

2

1

0

mysocialpulse @mysocial_pulse

over 5 years ago

@AG_Team00 $CKPT sentiment on twitter ... Positive closely followed by Negative.. indicate we can get a better entry point.. one might wait for a better entry point #stocks #daytrading #trading #investing #42sNotable #Stocks #CheckpointTherapeutics #DayTrading #Dogecoin

mysocial_pulse's tweet photo. @AG_Team00 $CKPT sentiment on twitter ... Positive closely followed by Negative.. indicate we can get a better entry point.. one might wait for a better entry point #stocks
#daytrading
#trading
#investing
#42sNotable
#Stocks
#CheckpointTherapeutics
#DayTrading
#Dogecoin https://t.co/lfpTAlFBMT

0

2

0

1stOncology @1stOncology

over 6 years ago

#CheckpointTherapeutics Announces Issuance of U.S. Composition of Matter #Patent for #AntiPDL1Antibody #Cosibelimab $CKPT https://t.co/YREdhzqMH8

0

1

0

1stOncology @1stOncology

about 8 years ago

#CheckpointTherapeutics Announces Clinical Data on EGFR Inhibitor #CK101 Selected for Late-Breaking Oral Presentation at #IASLC18 https://t.co/NqjJQ9bFJa

0

2

1

0

Sarah Cannon Docs @SarahCannonDocs

about 8 years ago

CK-101 (RX518), a Third Generation Mutant-Selective Inhibitor of EGFR in NSCLC: Results of an Ongoing Phase I/II Trial accepted for #WCLC2018 with @MLJohnsonMD2 @mljohnsonmd and #CheckpointTherapeutics https://t.co/tUpDX3vrNK

0

3

0